Malignant pheochromocytoma: Current status and initiatives for future progress

Endocrine-Related Cancer

Volumn 11, Issue 3, 2004, Pages 423-436

  Eisenhofer, Graeme ^a   Bornstein, Stefan R ^b   Brouwers, Frederieke M ^a   Cheung, Nai Kong V ^c   Dahia, Patricia L ^d   De Krijger, Ronald R ^e   Giordano, Thomas J ^f   Greene, Lloyd A ^g   Goldstein, David S ^a   Lehnert, Hendrik ^h   Manger, William M ⁱ   Maris, John M ^j   Neumann, Hartmut P H ^k   Pacak, Karel ^a   Shulkin, Barry L ^g   Smith, David I ^l   Tischler, Arthur S ^m   Young Jr , William F ^l  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF MICHIGAN   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

ⁱ National Hypertension Association   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k UNIVERSITY OF FREIBURG   (Germany)

^l MAYO CLINIC   (United States)

^m TUFTS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTIHYPERTENSIVE AGENT; CISPLATIN; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DACARBAZINE; GAMMA INTERFERON; GENE PRODUCT; HALOFUGINONE; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IODINE 131; METIROSINE; NERVE CELL ADHESION MOLECULE; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN RET; PROTEIN SDHB; PROTEIN SDHD; RESERPINE; RETINOIC ACID; SECRETOGRANIN II; TELOMERASE REVERSE TRANSCRIPTASE; TENASCIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VINCRISTINE SULFATE; VON HIPPEL LINDAU PROTEIN;

CANCER SURGERY; CARCINOGENESIS; CATECHOLAMINE RELEASE; CHEMOEMBOLIZATION; DIAGNOSTIC VALUE; FUTUROLOGY; GENETIC DISORDER; GENOMICS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; MULTICENTER STUDY; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; PHEOCHROMOCYTOMA; PREDICTION; PROGNOSIS; RADIOFREQUENCY; RARE DISEASE; REVIEW; SIDE EFFECT;

ADRENAL GLAND NEOPLASMS; FORECASTING; HUMANS; PHEOCHROMOCYTOMA;

EID: 4944220064     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00829     Document Type: Review

References (92)

1. Aguiar RC, Cox G, Pomeroy SL & Dahia PL 2001 Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL 1), in pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 2890-2894.
2. Anton AH, Greer M, Sayre DF & Williams CM 1967 Dihydroxyphenylalanine secretion in a malignant pheochromocytoma. American Journal of Medicine 42 469-475.
3. Armour A, Cunningham SH, Gaze MN, Wheldon TE & Mairs RJ 1997 The effect of cisplatin pretreatment on the accumulation of MIBG by neuroblastoma cells in vitro. British Journal of Cancer 75 470-476.
4. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R & Keiser HR 1988 Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Annals of Internal Medicine 109 267-273.
5. Baba T, Machida K, Ozaki I, Okushima T, Murabayashi S, Kamata Y, Imamura K & Takebe K 1985 A malignant pheochromocytoma with ileus, polyuria and hypercalcemia: a case of recurrence 17 years after the initial operation. Endocrinology Japan 32 337-345.
6. Bauters C, Vantygheum M-C, Leteurtre E, Odou M-F, Mouton C, Porchet N, Wemeau J-L, Proye C & Pigny P 2003 Hereditary phaeochromocytoma and paragangliomas: a study of five susceptibility genes. Journal of Medical Genetics 40 e75.
7. Benn DE, Dwight T, Richardson AL, Delbridge L, Bambach CP, Stowasser M, Gordon RD, Marsh DJ & Robinson BG 2000 Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Research 60 7048-7051.
8. Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, Mawrin C, Hoang-Vu C, Roessner A & Lehnert H 2003 Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 88 4280-4286.
9. 131I]MIBG and clonogenic cell kill. Oncogene 20 7804-7808.
10. Brauch H, Hoeppner W, Jahnig H, Wohl T, Engelhardt D, Speisberg F & Ritter MM 1997 Sporadic pheochromocytomas are rarely associated with germline mutations in the vh1 tumor suppressor gene or the ret protooncogene. Journal of Clinical Endocrinology and Metabolism 82 4101-4104.
11. van den Broek PJ & de Graeff J 1978 Prolonged survival in a patient with pulmonary metastases of a malignant pheochromocytoma. Netherlands Journal of Medicine 21 245-247.
12. Brown WJ, Barajas L, Waisman J & De Quattro V 1972 Ultrastructural and biochemical correlates of adrenal and extra-adrenal pheochromocytoma. Cancer 29 744-759.
13. Bryant J, Farmer J, Kessler LJ, Townsend RR & Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute 95 1196-1204.
14. Chevinsky AH, Minion JP & Falko JM 1990 Metastatic pheochromocytoma associated with multiple endocrine neoplasia syndrome type II. Archives of Surgery 125 935-938.
15. Cunningham S, Boyd M, Brown MM, Carlin S, McCluskey A, Livingstone A, Mairs RJ & Wheldon TE 2000 A gene therapy approach to enhance the targeted radiotherapy of neuroblastoma. Medical and Pediatric Oncology 35 708-711.
16. Dannenberg H, Speel EJ, Zhao J, Saremaslani P, van Der Harst E, Roth J, Heitz PU, Bonjer HJ, Dinjens WN, Mooi WJ, Komminoth P & de Krijger RR 2000 Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. American Journal of Pathology 157 353-359.
17. Decoulx M, Wemeau JL, Racadot-Leroy N, Grimbert I, Proye C & Plane C 1987 Alpha-methyl-paratyrosine in the treatment of malignant pheochromocytoma. Reveu Medecine Interne 8 383-388.
18. Edstrom Elder E, Hjelm Skog AL, Hoog A & Hamberger B 2003 The management of benign and malignant pheochromocytoma and abdominal paraganglioma. European Journal of Surgical Oncology 29 278-283.
19. Eisenhofer G, Walther MM, Huynh TT, Li ST, Bornstein SR, Vortmeyer A, Mannelli M, Goldstein DS, Linehan WM, Lenders JW & Pacak K 2001 Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. Journal of Clinical Endocrinology and Metabolism 86 1999-2008.
20. Eisenhofer G, Huynh T-T, Pacak K, Brouwers FM, Walther MM, Linehan WM, Munson PJ, Mannelli M, Goldstein DS & Elkahloun AG 2004 Distinct gene expression profiles in norepinephrine and epinephrine producing hereditary and sporadic pheochromocytomas: Activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine-Related Cancer (In Press).
21. Elder EE, Xu D, Hoog A, Enberg U, Hou M, Pisa P, Gruber A, Larsson C & Backdahl M 2003 KI-67 and hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma. Modern Pathology 16 246-255.
22. Favier J, Plouin PF, Corvol P & Gasc JM 2002 Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. American Journal of Pathology 161 1235-1246.
23. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF & Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 63 5615-5621.
24. Giordano TJ 2003 Gene expression profiling of endocrine tumors using DNA microarrays: progress and promise. Endocrine Pathology 14 107-116.
25. Goldstein DS, Stull R, Eisenhofer G, Sisson JC, Weder A, Averbuch SD & Keiser HR 1986 Plasma 3,4-dihydroxyphenylalanine (dopa) and catecholamines in neuroblastoma or pheochromocytoma. Annals of Internal Medicine 105 887-888.
26. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, Morgan WM 3rd, Neblett WW 3rd, Dates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN & Scott HW Jr 1999 Clinical experience over 48 years with pheochromocytoma. Annals of Surgery 229 755-766.
27. Greene LA & Tischler AS 1976 Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. PNAS 73 2424-2428.
28. Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, Neeman M, Pines M & Nagler A 2003 Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clinical Cancer Research 9 3788-3793.
29. van der Harst E, Bruining HA, Jaap Bonjer H, van der Ham F, Dinjens WN, Lamberts SW, de Herder WW, Koper JW, Stijnen T, Proye C, Lecomte-Houcke M, Bosman FT & de Krijger RR 2000 Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? Journal of Pathology 191 175-180.
30. 111In]octreotide uptake in benign and malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 685-693.
31. van der Harst E, de Herder WW, de Krijger RR, Bruining HA, Bonjer HJ, Lamberts SW, van den Meiracker AH, Stijnen TH & Boomsma F 2002 The value of plasma markers for the clinical behaviour of phaeochromocytomas. European Journal of Endocrinology 147 85-94.
32. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, Reincke M, Moser E & Neumann HP 2002 Pheochromocytomas: detection with 18F DOPA whole body PET - initial results. Radiology 222 507-512.
33. Hofstra RM, Stelwagen T, Stulp RP, de Jong D, Hulsbeek M, Kamsteeg EJ, van den Berg A, Landsvater RM, Vermey A, Molenaar WM, Lips CJ & Buys CH 1996 Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases. Journal of Clinical Endocrinology and Metabolism 81 2881-2884.
34. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 88 4083-4087.
35. Invitti C, De Martin I, Bolla GB, Pecori Giraldi F, Maestri E, Leonetti G & Cavagnini F 1993 Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors. Hormone Research 40 156-160.
36. Januszewicz W, Wocial B, Januszewicz A, Gryglas P & Prejbisz A 2001 Dopamine and dopa urinary excretion in patients with pheochromocytoma - diagnostic implications. Blood Pressure 10 212-216.
37. Jaques S Jr, Tobes MC & Sisson JC 1987 Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Research 47 3920-3928.
38. John H, Ziegler WH, Hauri D & Jaeger P 1999 Pheochromocytomas: can malignant potential be predicted? Urology 53 679-683.
39. 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma. Journal of Pediatrics and Hematological Oncology 25 769-773.
40. Khorram-Manesh A, Ahlman H, Jansson S & Nilsson O 2002 N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocrine Pathology 13 99-110.
41. Kimura N & Sasano N 1990 A comparative study between malignant and benign pheochromocytoma using morphometry, cytophotometry, and immunohistochemistry. In Endocrine Pathology Update, pp 99-117. Eds J Lechago & T Kameya. New York: Field & Wood.
42. Kimura N, Sasano N, Miura Y & Kobayashi K 1984 Adrenal and extra-adrenal pheochromocytomas: an ultrastructural and formaldehyde-induced fluorescence study with catecholamine content. Tohoku Journal of Experimental Medicine 142 1-14.
43. Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, Forssell-Aronsson E & Nilsson O 2003 Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. British Journal of Cancer 89 1383-1388.
44. Kopf D, Bockisch A, Steinert H, Hahn K, Beyer J, Neumann HP, Hensen J & Lehnert H 1997 Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clinical Endocrinology 46 39-44.
45. 131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. Journal of Clinical Endocrinology and Metabolism 72 455-461.
46. Lack EE, Lloyd RV, Carney JA & Woodruff JW 2003 Recommendations for the reporting of extra-adrenal paragangliomas. The Association of Directors of Anatomic and Surgical Pathology. Human Pathology 34 112-113.
47. Lamarre-Cliche M, Gimenez-Roqueplo AP, Billaud E, Baudin E, Luton JP & Plouin PF 2002 Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma. Clinical Endocrinology 57 629-634.
48. Lehnert H, Mundschenk J & Hahn K 2004 Malignant pheochromocytoma. Frontiers of Hormone Research 31 155-162.
49. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, Goldstein DS & Eisenhofer G 2002 Biochemical diagnosis of pheochromocytoma: which test is best? Journal of the American Medical Association 287 1427-1434.
50. Linnoila RI, Keiser HR, Steinberg SM & Lack EE 1990 Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Human Pathology 21 1168-1180.
51. 131I-MIBG): a comprehensive review of 116 reported patients. Journal of Endocrinological Investigation 20 648-658.
52. McNeil AR, Blok BH, Koelmeyer TD, Burke MP & Hilton JM 2000 Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Australian and New Zealand Journal of Medicine 30 648-652.
53. Maloney A & Workman P 2002 HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opinion in Biological Therapeutics 2 3-24.
54. Manger WM & Gifford RW 1996 Clinical and Experimental Pheochromocytoma. Cambridge, MA: Blackwell Science.
55. 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. Journal of Clinical Oncology 16 229-236.
56. Mishra AK, Agarwal G, Kapoor A, Agarwal A, Bhatia E & Mishra SK 2000 Catecholamine cardiomyopathy in bilateral malignant pheochromocytoma: successful reversal after surgery. International Journal of Cardiology 76 89-90.
57. Miskulin J, Shulkin BL, Doherty GM, Sisson JC, Burney RE & Gauger PG 2003 Is preoperative iodine 123 metaiodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma? Surgery 134 913-922.
58. Montaldo PG, Raffaghello L, Guarnaccia F, Pistoia V, Gara venta A & Ponzoni M 1996 Increase of metaiodobenzylguanidine uptake and intracellular half-life during differentiation of human neuroblastoma cells. International Journal of Cancer 67 95-100.
59. Morikawa T, Suzuki M, Unno M, Endo K, Katayose Y & Matsuno S 2001 Malignant pheochromocytoma with hepatic metastasis diagnosed 10 years after a resection of the primary incidentaloma adrenal lesion: report of a case. Surgery Today 31 80-84.
60. Mundschenk J, Unger N, Schulz S, Hollt V, Steinke R & Lehnert H 2003 Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 88 5150-5157.
61. 18F]FDG and 82Rb. Journal of Computational Assisted Tomography 20 312-316.
62. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M & Szmigielski C 2002 Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 346 1459-1466.
63. Nonaka K, Makuuchi H, Naruse Y, Kobayashi T & Goto M 2000 Surgical excision of malignant pheochromocytoma in the left atrium. Japanese Journal of Thoracic Cardiovascular Surgery 48 126-128.
64. Pacak K, Fojo T, Goldstein DS, Eisenhofer G, Walther MM, Linehan WM, Bachenheimer L, Abraham J & Wood BJ 2001 Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. Journal of the National Cancer Institute 93 648-649.
65. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, Hedrick-Ellenson L & Parsons R 2001 An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/-mice. PNAS 98 10320-10325.
66. Powers JF, Evinger MJ, Tsokas P, Bedri S, Alroy J, Shahsavari M & Tischler AS 2000 Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell and Tissue Research 302 309-320.
67. Powers JF, Schelling K, Brachold JM, Tsokas P, Schayek H, Friedman E & Tischler AS 2002 High-level expression of receptor tyrosine kinase Ret and responsiveness to Ret-activating ligands in pheochromocytoma cell lines from neurofibromatosis knockout mice. Molecular and Cellular Neuroscience 20 382-389.
68. Rao F, Reiser HR & O'Connor DT 2000 Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 36 1045-1052.
69. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA & Fitzgerald PA 2003 High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98 239-248.
70. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, Tyler DS & Olson JA Jr 2003 Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134 956-962.
71. Salmenkivi K, Haglund C, Arola J & Heikkila P 2001a Increased expression of tenascin in pheochromocytomas correlates with malignancy. American Journal of Surgical Pathology 25 1419-1423.
72. Salmenkivi K, Haglund C, Ristimaki A, Arola J & Heikkila P 2001b Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. Journal of Clinical Endocrinology and Metabolism 86 5615-5619.
73. Salmenkivi K, Heikkila P, Liu J, Haglund C & Arola J 2003 VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. Apmis 111 458-464.
74. Sausville EA, Tomaszewski JE & Ivy P 2003 Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Current Cancer Drug Targets 3 377-383.
75. Schlumberger M, Gicquel C, Lumbroso J, Tenenbaum F, Comoy E, Bosq J, Fonseca E, Ghillani PP, Aubert B, Travagli JP et al. 1992 Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. Journal of Endocrinological Investigation 15 631-642.
76. 131I]metaiodobenzylguanidine: results from ten years of experience. Journal of Nuclear and Biological Medicine 35 269-276.
77. Shapiro B, Gross MD & Shulkin B 2001 Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends in Endocrinology and Metabolism 12 469-475.
78. Sisson JC, Shapiro B, Shulkin BL, Urba S, Zempel S & Spaulding S 1999 Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy. American Journal of Clinical Oncology 22 364-370.
79. Smith-Hicks CL, Sizer KC, Powers JF, Tischler AS & Costantini F 2000 C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO Journal 19 612-622.
80. Takahashi K, Ashizawa N, Minami T, Suzuki S, Sakamoto I, Hayashi K, Tomiyasu S, Sumikawa K, Kitamura K, Eto T & Yano K 1999 Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Internal Medicine 38 349-354.
81. Tanaka S, Ito T, Tomoda J, Higashi T, Yamada G & Tsuji T 1993 Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion. Internal Medicine 32 789-794.
82. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PF, Caillou B & Parmentier C 1995 Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. Journal of Nuclear Medicine 36 1-6.
83. Thompson LD 2002 Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. American Journal of Surgical Pathology 26 551-566.
84. 131I]Metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. Journal of Nuclear and Biological Medicine 35 295-299.
85. Walther MM, Herring J, Enquist E, Keiser HR & Linehan WM 1999 Von Recklinghausen's disease and pheochromocytomas. Journal of Urology 162 1582-1586.
86. Wiseman GA & Kvols LK 1995 Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Seminars in Nuclear Medicine 25 272-278.
87. Yon L, Guillemot J, Montero-Hadjadje M, Grumolato L, Leprince J, Lefebvre H, Contesse V, Plouin PF, Vaudry H & Anouar Y 2003 Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. Journal of Clinical Endocrinology and Metabolism 88 2579-2585.
88. Yoshida S, Hatori M, Noshiro T, Kimura N & Kokubun S 2001 Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma. Archives of Orthopedic Trauma and Surgery 121 598-600.
89. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L & DePinho RA 2002 Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. PNAS 99 1455-1460.
90. Zerhouni E 2003 Medicine. The NIH Roadmap. Science 302 63-72.
91. Zielke A, Bresalier RS, Siperstein AE, Clark OH, Rothmund M & Duh QY 1998 A unique allogenic model of metastatic pheochromocytoma: PC12 rat pheochromocytoma xenografts to nude mice and establishment of metastases-derived PC12 variants. Clinical and Experimental Metastasis 16 341-352.
92. Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I, Wunderlich A, Hofbauer LC & Duh QY 2002 VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132 1056-1063.